Dyax issued fifth U.S. patent for Phage Display

By Angela McDaniels

Seattle, Jan. 10 - Dyax Corp. said the U.S. Patent and Trademark office has issued the company's fifth U.S. patent covering its proprietary Phage Display technology, which rapidly selects compounds that bind to specific therapeutic targets.

The new patent - U.S. Patent No. 6,979,538 - covers methods for displaying antibodies on filamentous bacteriophage.

In addition to its five U.S. patents, Dyax said it holds several patents for Phage Display in Canada and Israel, with pending applications in other countries.

"This recently issued patent adds to Dyax's already dominant patent position in the phage display field. Our discovery technology platform continues to provide Dyax and our collaborators the ability to take almost any target of interest and identify novel compounds that selectively bind to it," Ivana Magovcevic-Liebisch, general counsel and executive vice president of corporate communications, said in a company news release.

"For example, our human antibody phage display libraries can be screened against a selected target to identify high-affinity antibodies that can be developed as new therapeutics," Magovcevic-Liebisch added.

Dyax is a biotechnology company based in Cambridge, Mass., that uses its proprietary drug discovery technology to identify antibody, small protein and peptide compounds for clinical development.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.